Novartis initiates tolerability study of ianalumab with TPO-RA in ITP patients
A new study is assessing the tolerability of ianalumab combined with investigator's choice TPO-RA in ITP patients.
Asset / Drug
Drug and asset intelligence for ianalumab with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.